Abatacept retention and clinical effectiveness in patients with rheumatoid arthritis in a real‐world setting in Taiwan
Aim To evaluate real‐world abatacept retention and clinical outcomes in patients with rheumatoid arthritis in Taiwan. Methods This prospective, observational study enrolled patients with rheumatoid arthritis aged ≥20 years who received abatacept in real‐world practice. The primary endpoint was the a...
Gespeichert in:
| Veröffentlicht in: | International journal of rheumatic diseases 2024-07, Vol.27 (7), p.e15199-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 7 |
| container_start_page | e15199 |
| container_title | International journal of rheumatic diseases |
| container_volume | 27 |
| creator | Chen, Kun‐Hung Li, Ko‐Jen Fang, Yao‐Fan Hsieh, Song‐Chou Chen, Ying‐Chou Lee, Chyou‐Shen Luo, Shue‐Fen Cheng, Tien‐Tsai Tsai, Wen Chan Lo, Yu‐Chen Lan, Joung‐Liang |
| description | Aim
To evaluate real‐world abatacept retention and clinical outcomes in patients with rheumatoid arthritis in Taiwan.
Methods
This prospective, observational study enrolled patients with rheumatoid arthritis aged ≥20 years who received abatacept in real‐world practice. The primary endpoint was the abatacept retention rate at 24 months. Patients were categorized into subgroups based on abatacept treatment status and previous biological disease‐modifying antirheumatic drug (bDMARD) therapy. Risk factors affecting abatacept retention were determined by regression analysis.
Results
A total of 212 patients were enrolled. The overall abatacept retention rate at 24 months among all patients was 59.9% (95% confidence interval 53.0%–66.6%). Patients who were ongoing users of abatacept and bDMARD‐naïve had the highest retention rate (76.3%); of these, 31.6% achieved low disease activity or remission after 2 years. Previous treatment with bDMARDs was associated with an increased risk of abatacept discontinuation (hazard ratio 1.99; p = .002). The most common reasons for abatacept discontinuation were drug switch (11.3%) and loss to follow‐up (6.1%). Abatacept was well‐tolerated with no new safety signals.
Conclusion
The 24‐month retention rate of abatacept was 59.9%; abatacept was associated with improved clinical outcomes and was well‐tolerated in the real‐world setting in Taiwan. |
| doi_str_mv | 10.1111/1756-185X.15199 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3081291965</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3081291965</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3259-d00a603c688cd58fa0ca98d9ed138a9f5f2dadbf40d03d947efd2e9fe5baae263</originalsourceid><addsrcrecordid>eNqFkcFOGzEQhq2qiADl3FtlqZdeEuzd9WZ9jFBbkCLBAaTerIk9bhxtvKntJc2NR-AZ-yR4Cc2BC76MZX_zaTQ_IZ85m_B8LvhU1GPeiF8TLriUH8jJ4eXj4V7xETmNccVYzct6ekxGpWScNVyckL-zBSTQuEk0YEKfXOcpeEN167zT0FK0FnVyD-gxRuo83UByGYx069KShiX2a0idMxRCWgaX3AsF2Qftv8enbRdaQyOm5Pzv4ecO3Bb8J3JkoY14_lrPyP2P73eXV-P5zc_ry9l8rMtCyLFhDGpW6rpptBGNBaZBNkai4WUD0gpbGDALWzHDSiOrKVpToLQoFgBY1OUZ-bb3bkL3p8eY1NpFjW0LHrs-qjLvoZBc1iKjX9-gq64PPk83UJWQ07rimbrYUzp0MQa0ahPcGsJOcaaGUNSwdjVEoF5CyR1fXr39Yo3mwP9PIQNiD2xdi7v3fGp2O9-LnwHSLppt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3084597641</pqid></control><display><type>article</type><title>Abatacept retention and clinical effectiveness in patients with rheumatoid arthritis in a real‐world setting in Taiwan</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Chen, Kun‐Hung ; Li, Ko‐Jen ; Fang, Yao‐Fan ; Hsieh, Song‐Chou ; Chen, Ying‐Chou ; Lee, Chyou‐Shen ; Luo, Shue‐Fen ; Cheng, Tien‐Tsai ; Tsai, Wen Chan ; Lo, Yu‐Chen ; Lan, Joung‐Liang</creator><creatorcontrib>Chen, Kun‐Hung ; Li, Ko‐Jen ; Fang, Yao‐Fan ; Hsieh, Song‐Chou ; Chen, Ying‐Chou ; Lee, Chyou‐Shen ; Luo, Shue‐Fen ; Cheng, Tien‐Tsai ; Tsai, Wen Chan ; Lo, Yu‐Chen ; Lan, Joung‐Liang</creatorcontrib><description>Aim
To evaluate real‐world abatacept retention and clinical outcomes in patients with rheumatoid arthritis in Taiwan.
Methods
This prospective, observational study enrolled patients with rheumatoid arthritis aged ≥20 years who received abatacept in real‐world practice. The primary endpoint was the abatacept retention rate at 24 months. Patients were categorized into subgroups based on abatacept treatment status and previous biological disease‐modifying antirheumatic drug (bDMARD) therapy. Risk factors affecting abatacept retention were determined by regression analysis.
Results
A total of 212 patients were enrolled. The overall abatacept retention rate at 24 months among all patients was 59.9% (95% confidence interval 53.0%–66.6%). Patients who were ongoing users of abatacept and bDMARD‐naïve had the highest retention rate (76.3%); of these, 31.6% achieved low disease activity or remission after 2 years. Previous treatment with bDMARDs was associated with an increased risk of abatacept discontinuation (hazard ratio 1.99; p = .002). The most common reasons for abatacept discontinuation were drug switch (11.3%) and loss to follow‐up (6.1%). Abatacept was well‐tolerated with no new safety signals.
Conclusion
The 24‐month retention rate of abatacept was 59.9%; abatacept was associated with improved clinical outcomes and was well‐tolerated in the real‐world setting in Taiwan.</description><identifier>ISSN: 1756-1841</identifier><identifier>ISSN: 1756-185X</identifier><identifier>EISSN: 1756-185X</identifier><identifier>DOI: 10.1111/1756-185X.15199</identifier><identifier>PMID: 39010815</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>abatacept ; Abatacept - adverse effects ; Abatacept - therapeutic use ; Adult ; Aged ; Antirheumatic Agents - adverse effects ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - diagnosis ; Arthritis, Rheumatoid - drug therapy ; Clinical outcomes ; clinical practice ; Drug Substitution ; Female ; Humans ; Male ; Medication Adherence ; Middle Aged ; Patients ; Prospective Studies ; real‐world ; Remission ; Remission Induction ; Retention ; Rheumatoid arthritis ; Risk Factors ; Taiwan ; Taiwan - epidemiology ; Time Factors ; Treatment Outcome</subject><ispartof>International journal of rheumatic diseases, 2024-07, Vol.27 (7), p.e15199-n/a</ispartof><rights>2024 Bristol‐Myers Squibb and The Author(s). published by Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.</rights><rights>2024 Bristol‐Myers Squibb and The Author(s). International Journal of Rheumatic Diseases published by Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3259-d00a603c688cd58fa0ca98d9ed138a9f5f2dadbf40d03d947efd2e9fe5baae263</cites><orcidid>0000-0002-8943-5056 ; 0000-0002-1418-2111 ; 0009-0005-0344-6133 ; 0009-0007-2019-5633 ; 0000-0002-2777-4298 ; 0000-0002-3449-1704 ; 0000-0002-4544-4620 ; 0000-0003-1608-7131</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2F1756-185X.15199$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2F1756-185X.15199$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39010815$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Kun‐Hung</creatorcontrib><creatorcontrib>Li, Ko‐Jen</creatorcontrib><creatorcontrib>Fang, Yao‐Fan</creatorcontrib><creatorcontrib>Hsieh, Song‐Chou</creatorcontrib><creatorcontrib>Chen, Ying‐Chou</creatorcontrib><creatorcontrib>Lee, Chyou‐Shen</creatorcontrib><creatorcontrib>Luo, Shue‐Fen</creatorcontrib><creatorcontrib>Cheng, Tien‐Tsai</creatorcontrib><creatorcontrib>Tsai, Wen Chan</creatorcontrib><creatorcontrib>Lo, Yu‐Chen</creatorcontrib><creatorcontrib>Lan, Joung‐Liang</creatorcontrib><title>Abatacept retention and clinical effectiveness in patients with rheumatoid arthritis in a real‐world setting in Taiwan</title><title>International journal of rheumatic diseases</title><addtitle>Int J Rheum Dis</addtitle><description>Aim
To evaluate real‐world abatacept retention and clinical outcomes in patients with rheumatoid arthritis in Taiwan.
Methods
This prospective, observational study enrolled patients with rheumatoid arthritis aged ≥20 years who received abatacept in real‐world practice. The primary endpoint was the abatacept retention rate at 24 months. Patients were categorized into subgroups based on abatacept treatment status and previous biological disease‐modifying antirheumatic drug (bDMARD) therapy. Risk factors affecting abatacept retention were determined by regression analysis.
Results
A total of 212 patients were enrolled. The overall abatacept retention rate at 24 months among all patients was 59.9% (95% confidence interval 53.0%–66.6%). Patients who were ongoing users of abatacept and bDMARD‐naïve had the highest retention rate (76.3%); of these, 31.6% achieved low disease activity or remission after 2 years. Previous treatment with bDMARDs was associated with an increased risk of abatacept discontinuation (hazard ratio 1.99; p = .002). The most common reasons for abatacept discontinuation were drug switch (11.3%) and loss to follow‐up (6.1%). Abatacept was well‐tolerated with no new safety signals.
Conclusion
The 24‐month retention rate of abatacept was 59.9%; abatacept was associated with improved clinical outcomes and was well‐tolerated in the real‐world setting in Taiwan.</description><subject>abatacept</subject><subject>Abatacept - adverse effects</subject><subject>Abatacept - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Antirheumatic Agents - adverse effects</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - diagnosis</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Clinical outcomes</subject><subject>clinical practice</subject><subject>Drug Substitution</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medication Adherence</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Prospective Studies</subject><subject>real‐world</subject><subject>Remission</subject><subject>Remission Induction</subject><subject>Retention</subject><subject>Rheumatoid arthritis</subject><subject>Risk Factors</subject><subject>Taiwan</subject><subject>Taiwan - epidemiology</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1756-1841</issn><issn>1756-185X</issn><issn>1756-185X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNqFkcFOGzEQhq2qiADl3FtlqZdeEuzd9WZ9jFBbkCLBAaTerIk9bhxtvKntJc2NR-AZ-yR4Cc2BC76MZX_zaTQ_IZ85m_B8LvhU1GPeiF8TLriUH8jJ4eXj4V7xETmNccVYzct6ekxGpWScNVyckL-zBSTQuEk0YEKfXOcpeEN167zT0FK0FnVyD-gxRuo83UByGYx069KShiX2a0idMxRCWgaX3AsF2Qftv8enbRdaQyOm5Pzv4ecO3Bb8J3JkoY14_lrPyP2P73eXV-P5zc_ry9l8rMtCyLFhDGpW6rpptBGNBaZBNkai4WUD0gpbGDALWzHDSiOrKVpToLQoFgBY1OUZ-bb3bkL3p8eY1NpFjW0LHrs-qjLvoZBc1iKjX9-gq64PPk83UJWQ07rimbrYUzp0MQa0ahPcGsJOcaaGUNSwdjVEoF5CyR1fXr39Yo3mwP9PIQNiD2xdi7v3fGp2O9-LnwHSLppt</recordid><startdate>202407</startdate><enddate>202407</enddate><creator>Chen, Kun‐Hung</creator><creator>Li, Ko‐Jen</creator><creator>Fang, Yao‐Fan</creator><creator>Hsieh, Song‐Chou</creator><creator>Chen, Ying‐Chou</creator><creator>Lee, Chyou‐Shen</creator><creator>Luo, Shue‐Fen</creator><creator>Cheng, Tien‐Tsai</creator><creator>Tsai, Wen Chan</creator><creator>Lo, Yu‐Chen</creator><creator>Lan, Joung‐Liang</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8943-5056</orcidid><orcidid>https://orcid.org/0000-0002-1418-2111</orcidid><orcidid>https://orcid.org/0009-0005-0344-6133</orcidid><orcidid>https://orcid.org/0009-0007-2019-5633</orcidid><orcidid>https://orcid.org/0000-0002-2777-4298</orcidid><orcidid>https://orcid.org/0000-0002-3449-1704</orcidid><orcidid>https://orcid.org/0000-0002-4544-4620</orcidid><orcidid>https://orcid.org/0000-0003-1608-7131</orcidid></search><sort><creationdate>202407</creationdate><title>Abatacept retention and clinical effectiveness in patients with rheumatoid arthritis in a real‐world setting in Taiwan</title><author>Chen, Kun‐Hung ; Li, Ko‐Jen ; Fang, Yao‐Fan ; Hsieh, Song‐Chou ; Chen, Ying‐Chou ; Lee, Chyou‐Shen ; Luo, Shue‐Fen ; Cheng, Tien‐Tsai ; Tsai, Wen Chan ; Lo, Yu‐Chen ; Lan, Joung‐Liang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3259-d00a603c688cd58fa0ca98d9ed138a9f5f2dadbf40d03d947efd2e9fe5baae263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>abatacept</topic><topic>Abatacept - adverse effects</topic><topic>Abatacept - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Antirheumatic Agents - adverse effects</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - diagnosis</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Clinical outcomes</topic><topic>clinical practice</topic><topic>Drug Substitution</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medication Adherence</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Prospective Studies</topic><topic>real‐world</topic><topic>Remission</topic><topic>Remission Induction</topic><topic>Retention</topic><topic>Rheumatoid arthritis</topic><topic>Risk Factors</topic><topic>Taiwan</topic><topic>Taiwan - epidemiology</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Kun‐Hung</creatorcontrib><creatorcontrib>Li, Ko‐Jen</creatorcontrib><creatorcontrib>Fang, Yao‐Fan</creatorcontrib><creatorcontrib>Hsieh, Song‐Chou</creatorcontrib><creatorcontrib>Chen, Ying‐Chou</creatorcontrib><creatorcontrib>Lee, Chyou‐Shen</creatorcontrib><creatorcontrib>Luo, Shue‐Fen</creatorcontrib><creatorcontrib>Cheng, Tien‐Tsai</creatorcontrib><creatorcontrib>Tsai, Wen Chan</creatorcontrib><creatorcontrib>Lo, Yu‐Chen</creatorcontrib><creatorcontrib>Lan, Joung‐Liang</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Kun‐Hung</au><au>Li, Ko‐Jen</au><au>Fang, Yao‐Fan</au><au>Hsieh, Song‐Chou</au><au>Chen, Ying‐Chou</au><au>Lee, Chyou‐Shen</au><au>Luo, Shue‐Fen</au><au>Cheng, Tien‐Tsai</au><au>Tsai, Wen Chan</au><au>Lo, Yu‐Chen</au><au>Lan, Joung‐Liang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abatacept retention and clinical effectiveness in patients with rheumatoid arthritis in a real‐world setting in Taiwan</atitle><jtitle>International journal of rheumatic diseases</jtitle><addtitle>Int J Rheum Dis</addtitle><date>2024-07</date><risdate>2024</risdate><volume>27</volume><issue>7</issue><spage>e15199</spage><epage>n/a</epage><pages>e15199-n/a</pages><issn>1756-1841</issn><issn>1756-185X</issn><eissn>1756-185X</eissn><abstract>Aim
To evaluate real‐world abatacept retention and clinical outcomes in patients with rheumatoid arthritis in Taiwan.
Methods
This prospective, observational study enrolled patients with rheumatoid arthritis aged ≥20 years who received abatacept in real‐world practice. The primary endpoint was the abatacept retention rate at 24 months. Patients were categorized into subgroups based on abatacept treatment status and previous biological disease‐modifying antirheumatic drug (bDMARD) therapy. Risk factors affecting abatacept retention were determined by regression analysis.
Results
A total of 212 patients were enrolled. The overall abatacept retention rate at 24 months among all patients was 59.9% (95% confidence interval 53.0%–66.6%). Patients who were ongoing users of abatacept and bDMARD‐naïve had the highest retention rate (76.3%); of these, 31.6% achieved low disease activity or remission after 2 years. Previous treatment with bDMARDs was associated with an increased risk of abatacept discontinuation (hazard ratio 1.99; p = .002). The most common reasons for abatacept discontinuation were drug switch (11.3%) and loss to follow‐up (6.1%). Abatacept was well‐tolerated with no new safety signals.
Conclusion
The 24‐month retention rate of abatacept was 59.9%; abatacept was associated with improved clinical outcomes and was well‐tolerated in the real‐world setting in Taiwan.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39010815</pmid><doi>10.1111/1756-185X.15199</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-8943-5056</orcidid><orcidid>https://orcid.org/0000-0002-1418-2111</orcidid><orcidid>https://orcid.org/0009-0005-0344-6133</orcidid><orcidid>https://orcid.org/0009-0007-2019-5633</orcidid><orcidid>https://orcid.org/0000-0002-2777-4298</orcidid><orcidid>https://orcid.org/0000-0002-3449-1704</orcidid><orcidid>https://orcid.org/0000-0002-4544-4620</orcidid><orcidid>https://orcid.org/0000-0003-1608-7131</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1756-1841 |
| ispartof | International journal of rheumatic diseases, 2024-07, Vol.27 (7), p.e15199-n/a |
| issn | 1756-1841 1756-185X 1756-185X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3081291965 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | abatacept Abatacept - adverse effects Abatacept - therapeutic use Adult Aged Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - diagnosis Arthritis, Rheumatoid - drug therapy Clinical outcomes clinical practice Drug Substitution Female Humans Male Medication Adherence Middle Aged Patients Prospective Studies real‐world Remission Remission Induction Retention Rheumatoid arthritis Risk Factors Taiwan Taiwan - epidemiology Time Factors Treatment Outcome |
| title | Abatacept retention and clinical effectiveness in patients with rheumatoid arthritis in a real‐world setting in Taiwan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T20%3A41%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abatacept%20retention%20and%20clinical%20effectiveness%20in%20patients%20with%20rheumatoid%20arthritis%20in%20a%20real%E2%80%90world%20setting%20in%20Taiwan&rft.jtitle=International%20journal%20of%20rheumatic%20diseases&rft.au=Chen,%20Kun%E2%80%90Hung&rft.date=2024-07&rft.volume=27&rft.issue=7&rft.spage=e15199&rft.epage=n/a&rft.pages=e15199-n/a&rft.issn=1756-1841&rft.eissn=1756-185X&rft_id=info:doi/10.1111/1756-185X.15199&rft_dat=%3Cproquest_cross%3E3081291965%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3084597641&rft_id=info:pmid/39010815&rfr_iscdi=true |